Tanabe Pharma
As of the edition of 20 October 2026, Tanabe Pharma runs 28 drugs, 8 of them marketed; it is on route A at 4 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Tanabe Pharma was merged.
The records place 2 company names in this family.
- Tanabe Pharma Corporation: merged
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Active | 10 |
| Went quiet | 5 |
| Stopped | 2 |
| Withdrawn from market | 1 |
| Status not established | 2 |
| Total | 28 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Levodopa | none listed | 4 |
| Canagliflozin anhydrous | Ends 2029 (patent) | 2 |
| Carbidopa anhydrous | none listed | 2 |
| Telaprevir | none listed | 0 |
| Cariprazine | Ends 2029 (patent) | 4 |
| Vadadustat | Ends 2034 (patent) | 4 |
| Teneligliptin | none listed | 0 |
| Inebilizumab | Ends 2032 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 4 targets, route B at 0 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Tanabe Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 32 trials led
- Hormones: 26 trials led
- Pregnancy and women's health: 22 trials led